Structured to Accelerate Innovation and
Commercialization Priorities
Creates New Roles to Oversee Product &
End-to-End Customer Experience and Technology
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the
global leader in tubeless insulin pump technology with its Omnipod®
brand of products, today announced its new organizational structure
designed to accelerate innovation and commercialization. The new
structure will be implemented during the second half of this year
with new leadership roles effective July 1, 2023. The leadership
team will continue to report to Jim Hollingshead, President and
Chief Executive Officer.
Mr. Hollingshead said, “It is an exciting time at Insulet as we
continue to advance our mission to improve the lives of people with
diabetes. Our Company has achieved remarkable growth, recently
accelerated by the U.S. commercial launch of our revolutionary
Omnipod® 5 Automated Insulin Delivery System, which we will soon
launch internationally. The global markets and customers we serve
have also rapidly evolved. Now is the ideal time to realign our
organizational structure to support our strong momentum, accelerate
our robust innovation pipeline, and drive continued global
expansion. Our new organizational design creates a more focused and
specialized structure that strengthens our commercial capabilities
and fosters further innovation and cross-functional
collaboration.”
As part of the new organizational structure, we have created the
following roles, effective July 1, 2023:
- Eric Benjamin has been named Chief Product & Customer
Experience Officer (CPXO), responsible for product vision and
execution, including franchise management and global growth
strategies, product and portfolio management, and driving the
end-to-end customer experience across the enterprise.
- Mark Field has been named Chief Technology Officer, responsible
for software and hardware engineering, information technology,
cyber security, digital and data services, and system architecture.
Mr. Field will be responsible for ensuring that we continue to have
robust software platforms, modules, and other technology
capabilities to support Insulet’s strategy and goals.
- The previous role of Chief Commercial Officer has been
separated into two leadership positions in order to drive more
focused regional and local market execution.
- The Company has commenced a search for a U.S. General Manager,
who will focus on accelerating our U.S. commercial growth,
go-to-market strategies, and sales operations. This newly created
role will also drive enhanced and consistent global commercial
capabilities across the enterprise.
- Patrick Crannell will continue in his role as International
General Manager overseeing the Company’s international commercial
operations. He is responsible for leading go-to-market execution
and expansion in international markets, as well as the strategic,
commercial, operational, and financial performance of the
international operations. Mr. Crannell will now report directly to
the CEO.
In connection with the internal reorganization, Bret
Christensen, Executive Vice President and Chief Commercial Officer,
is leaving the Company on May 5, 2023, to pursue other
opportunities. He has agreed to provide consulting services during
a transition period.
“Bret has played an integral role in the commercial successes of
the Company over the last six years, most recently with the U.S.
commercial launch of Omnipod 5 and the continued global expansion
of Omnipod DASH®,” said Mr. Hollingshead. “He helped build a deep,
talented commercial team that has contributed to our strong
customer base growth, an exceptional customer experience, and
differentiated business model and pharmacy channel access. All of
us at Insulet wish Bret well in his next endeavor.”
Mr. Hollingshead continued, “Consumer-focused innovation is
central to everything we do. As our business becomes larger and
more complex, we have structured our operations and leadership to
more efficiently and effectively drive and scale our innovations
and support our commercial and operational priorities. With the
changes announced today, Insulet is better positioned to continue
driving customer adoption, international expansion, and enhanced
customer experience as we support hundreds of thousands of people
with diabetes across the globe.”
First Quarter 2023 Financial Results
In a separate release today, Insulet reported financial results
for the first quarter of 2023. Management will host a conference
call today at 4:30 p.m. (Eastern Time) to discuss the financial
results and 2023 outlook.
About Eric Benjamin
Eric Benjamin combines his market knowledge and customer empathy
as he leads teams to deliver transformative technologies that drive
growth. He has served as Executive Vice President, Innovation,
Strategy and Digital Products since March 2022. Prior, he served in
roles of increasing responsibility since joining the Company in May
2015, including, Senior Vice President, Innovation and Strategy;
Senior Vice President, R&D, New Product Development and
Commercialization; Vice President, Procurement and Supplier
Development; and Director, Business Development. Prior to joining
Insulet, Mr. Benjamin held roles spanning R&D, Manufacturing,
and Quality with Abbott Laboratories. He earned a Bachelor of
Science in Industrial Engineering and Operations Research from the
University of California at Berkeley, a Master of Engineering in
Bioengineering from the University of California at San Diego, and
a Master of Business Administration from Harvard Business
School.
About Mark Field
Mark Field has more than 20 years of experience building and
leading high-performing software engineering teams that develop
complex, connected systems, and most recently served as Group Vice
President, Software Engineering, overseeing Insulet’s Mobile and
Cloud software teams since 2019. Prior to joining Insulet, Mr.
Field served as Chief Technology Officer at Thermo Fisher
Scientific, among other roles, where he led a global team
responsible for Thermo Fisher’s IoT connected device programs,
cloud-based scientific services, and E-commerce. Before joining
Thermo Fisher, Mr. Field was an executive at Oracle Corporation.
Mr. Field holds degrees in Computer Science and Business from the
University of Auckland in New Zealand.
About Patrick Crannell
Patrick Crannell has vast experience managing operations
internationally having spent 10 years living and working in Europe
and the Middle East. Through various general manager and commercial
roles, he has served as Insulet’s Senior Vice President, Head of
International since August 2022. Prior to joining Insulet, Mr.
Crannell served as Vice President of Infusion Therapy and Medical
Devices at ICU Medical, where he led a large U.S. team and drove
record growth through implementation of a new commercial model and
aligned incentives across three different business units. Prior, he
was Vice President, General Manager, of ICU’s Infusion Consumables
Business Unit, which operated in more than 60 countries, with
direct affiliate and distributor teams. Before joining ICU Medical,
he was Vice President, International with Pfizer in London and
previously served as Vice President for Hospira (later acquired by
Pfizer), overseeing the UK, Ireland, Benelux, and Compounding
businesses. Mr. Crannell earned a Master’s degree in Business
Administration, with a concentration in Management, from the
University of St. Thomas in St. Paul, Minnesota.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
Massachusetts, is an innovative medical device company dedicated to
simplifying life for people with diabetes and other conditions
through its Omnipod product platform. The Omnipod Insulin
Management System provides a unique alternative to traditional
insulin delivery methods. With its simple, wearable design, the
tubeless disposable Pod provides up to three days of non-stop
insulin delivery, without the need to see or handle a needle.
Insulet’s flagship innovation, the Omnipod® 5 Automated Insulin
Delivery System, integrates with a continuous glucose monitor to
manage blood sugar with no multiple daily injections, zero
fingersticks, and can be controlled by a compatible smartphone or
Omnipod 5 Controller. Insulet also leverages the unique design of
its Pod by tailoring its Omnipod technology platform for the
delivery of non-insulin subcutaneous drugs across other therapeutic
areas. For more information, please visit: insulet.com and
omnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations, intentions,
beliefs, or strategies regarding the future. These forward-looking
statements are based on its current expectations and beliefs
concerning future developments and their potential effects on
Insulet. There can be no assurance that future developments
affecting Insulet will be those that it has anticipated. These
forward-looking statements involve a number of risks, uncertainties
(some of which are beyond its control) or other assumptions that
may cause actual results or performance to be materially different
from those expressed or implied by these forward-looking
statements, and other risks and uncertainties described in its
Annual Report on Form 10-K, which was filed with the Securities and
Exchange Commission on February 24, 2023 in the section entitled
"Risk Factors," and in its other filings from time to time with the
Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its
assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking statements.
Insulet undertakes no obligation to publicly update or revise any
forward-looking statements.
©2023 Insulet Corporation. Omnipod, Omnipod 5 and Omnipod DASH
are registered trademarks of Insulet Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230504005361/en/
Investor Relations: Deborah R. Gordon Vice President,
Investor Relations (978) 600-7717 dgordon@insulet.com
Media: Angela Geryak Wiczek Senior Director, Corporate
Communications (978) 932-0611 awiczek@insulet.com
Insulet (NASDAQ:PODD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Insulet (NASDAQ:PODD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024